Idiopathic Pulmonary Fibrosis Treatment Market Report

Idiopathic Pulmonary Fibrosis Treatment Market Analysis, Market Size, Drug Class Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2026

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: GVR5818
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

Global Idiopathic Pulmonary Fibrosis (IPF) treatment market is estimated to increase at a significant rate over the forecast period. IPF is a rare disease but one of the most common forms of interstitial lung diseases. Growing geriatric population is one of the key drivers expected to drive the market growth.

Increasing prevalence of IPF is anticipated to propel the market. According to the National Institutes of Health (NIH), nearly 30,000 to 40,000 new cases of IPF are diagnosed each year and 100,000 people are affected in the U.S. Furthermore, commercialization of novel drugs and surge in cigarette smoking population are some of the other key factors expected to boost the market growth over the forecast period.

Aging is considered as the greatest risk factor for development. Hence, the fact that the global base of geriatric population is expected to grow over the next six years is expected to serve this market as a high impact rendering driver. According to the World Population Aging Report 2015 by United Nations, the number of elderly people aged 60 years and above is expected to grow by 56%, i.e., from 901 million in 2015 to 1.4 billion in 2030. In addition, the number of elderly people aged 80 and over is projected to triple by 2050 and will reach 434 million.

On the basis of drug class, the market is segmented into antifibrotic, tyrosine kinase inhibitors, and autotaxin inhibitors. Presence of strong pipeline is likely to have a positive impact on the segment growth. Esbriet by F. Hoffman La Roche and Ofev by Boehringer Ingelheim International GmbH are the only drugs approved by the FDA for the treatment of IPF.

Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East Asia. North America is estimated to hold the largest market share in 2018 owing to the increasing prevalence of IPF and growing awareness regarding the available treatment options. Major industry participants include F. Hoffman La Roche, Boehringer Ingelheim International GmbH, MediciNova, Inc, Promedior, Inc., Merck & Co., Inc., Biogen, Prometic Life Sciences Inc., Cipla, Inc., and Bristol-Myers Squibb Company.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified